A 42-year-old woman with acute necrotizing pancreatitis secondary to hypertriglyceridaemia (serum triglycerides 2800 mg/dL) is on supportive care. She develops acute kidney injury (creatinine 2.1 mg/dL) and persistent hypoxia (SpO₂ 88% on room air). She is haemodynamically stable. For management of the underlying metabolic derangement driving pancreatitis severity, which agent is the drug of choice?

Explanation

## Acute Management of Severe Hypertriglyceridaemia-Induced Pancreatitis ### Rationale for Insulin + Dextrose **Key Point:** Insulin infusion with dextrose is the first-line pharmacological agent for acute reduction of serum triglycerides in hypertriglyceridaemia-induced acute pancreatitis, especially when triglycerides exceed 1500 mg/dL. **High-Yield:** Insulin activates lipoprotein lipase (LPL), the rate-limiting enzyme for triglyceride hydrolysis. This rapidly lowers triglyceride levels within hours, reducing pancreatic lipotoxicity and preventing further inflammation. The dextrose prevents hypoglycaemia and provides substrate for LPL activation. ### Mechanism of Action 1. Insulin suppresses hepatic VLDL production (reduces apoB-100 secretion) 2. Insulin activates lipoprotein lipase in adipose and muscle tissue 3. Enhanced triglyceride hydrolysis to free fatty acids and glycerol 4. Serum triglycerides typically fall 30–50% within 24–48 hours ### Clinical Protocol - **Dosing:** Insulin 0.1–0.2 units/kg/hr IV infusion with concurrent dextrose (D50W or D10W) to maintain glucose 150–250 mg/dL - **Monitoring:** Check triglycerides and glucose every 4–6 hours initially - **Target:** Reduce triglycerides to <500 mg/dL to halt pancreatitis progression - **Duration:** Continue until triglycerides stabilize and pancreatitis resolves ### Comparison of Therapeutic Options | Agent | Onset | Efficacy | Indication | Limitation | |-------|-------|----------|-----------|------------| | Insulin + dextrose | Hours | 30–50% reduction in 24–48 hrs | **First-line acute** | Requires ICU monitoring | | Atorvastatin | Days–weeks | Modest chronic reduction | Long-term prevention | Too slow for acute crisis | | Gemfibrozil | Days–weeks | Moderate chronic reduction | Long-term prevention | Too slow for acute crisis | | Plasmapheresis | Hours | 60–80% reduction | Refractory cases (TG >1500 + severe) | Invasive, reserved for failure of medical therapy | **Clinical Pearl:** Plasmapheresis is reserved for patients with triglycerides >1500 mg/dL who fail to respond to insulin/dextrose within 24–48 hours or who have recurrent pancreatitis. This patient is a candidate for insulin first. **Warning:** Do NOT use statins or fibrates as acute monotherapy—they work over days to weeks and are ineffective in the acute setting. They are used for long-term secondary prevention after acute phase resolution. ### Why This Patient Needs Acute Intervention With triglycerides >2500 mg/dL and evidence of severe pancreatitis (necrotizing, AKI, hypoxia), rapid triglyceride reduction is critical to prevent multi-organ failure. Insulin + dextrose is the only agent that achieves this within hours. [cite:Harrison 21e Ch 346; Tenner S, et al. American College of Gastroenterology guideline for acute pancreatitis. Am J Gastroenterol. 2013.]